

# INDEX

<b>INDEX</b> .....	<b>5</b>
<b>AIMS AND ORGANIZATION OF THE THESIS</b> .....	<b>10</b>
<b>ZIELSETZUNG UND AUFBAU DER DISSERTATION</b> .....	<b>11</b>
<b>1 INTRODUCTION</b> .....	<b>12</b>
<b>2 PRINCIPLES OF DERMATOLOGICAL FORMULATIONS</b> .....	<b>17</b>
<b>2.1 Anatomy and physiology of the skin</b> .....	<b>17</b>
<b>2.2 Drug penetration through the skin</b> .....	<b>20</b>
<b>2.3 Drug delivery from topical formulations</b> .....	<b>25</b>
<b>2.4 Innovative solid lipid carriers for topical drug delivery</b> .....	<b>25</b>
2.4.1 Morphological description of SLN and NLC.....	26
2.4.1.1 Models of drug incorporation into SLN.....	26
2.4.1.2 Models of drug incorporation into NLC.....	28
2.4.2 Description of the preparation methods of SLN and NLC.....	29
2.4.2.1 High pressure homogenization technique.....	29
2.4.2.1.1 Hot high pressure homogenization.....	31
2.4.2.1.2 Cold high pressure homogenization.....	33
2.4.2.2 Microemulsions based SLN.....	35
2.4.2.3 Solvent emulsification-evaporation technique.....	37
2.4.2.4 Solvent displacement technique.....	39
2.4.2.5 Emulsification-diffusion technique.....	40
2.4.2.6 Phase inversion-based technique.....	42
<b>2.5 Problems of production and stability of SLN and NLC</b> .....	<b>43</b>
2.5.1 Lipid polymorphism.....	43
2.5.2 Risk of gelation.....	46

<b>3 MATERIALS AND METHODS.....</b>	<b>47</b>
<b>3.1 Materials .....</b>	<b>47</b>
3.1.1 Lipid materials.....	47
3.1.1.1 Dynasan <sup>®</sup> 116.....	47
3.1.1.2 Compritol <sup>®</sup> 888 ATO .....	48
3.1.1.3 Miglyol <sup>®</sup> 812 .....	48
3.1.1.4 $\alpha$ -Tocopherol .....	48
3.1.2 Emulsifying agents.....	49
3.1.2.1 Tyloxapol <sup>®</sup> .....	49
3.1.2.2 Lutrol <sup>®</sup> F68.....	49
3.1.2.3 Sodium deoxycholate .....	50
3.1.3 Gel forming agent.....	50
3.1.4 Antifungal agents .....	51
3.1.4.1 Clotrimazole .....	51
3.1.4.2 Ketoconazole.....	52
3.1.5 Other materials .....	53
3.1.5.1 Commercial creams.....	53
3.1.5.2 Glycerol.....	53
3.1.5.3 Trizma <sup>®</sup> pre-set crystals .....	53
3.1.5.4 Methyl paraben.....	54
3.1.5.5 Water .....	54
<b>3.2 Methods .....</b>	<b>54</b>
3.2.1 Preparation of aqueous SLN and NLC dispersions.....	54
3.2.2 Preparation of SLN- and NLC-based semi-solid formulations.....	56
3.2.3 Measurement of particle size and zeta potential .....	57
3.2.3.1 Laser diffractometry .....	57
3.2.3.2 Photon correlation spectroscopy .....	60
3.2.3.3 Zeta potential and electrophoretic mobility .....	63
3.2.4 Imaging analysis.....	65
3.2.4.1 Light microscopy analysis.....	66
3.2.4.2 Scanning electron microscopy analysis.....	66
3.2.5 Thermal analysis .....	67
3.2.5.1 Thermal gravimetry analysis.....	67

3.2.5.2	Differential scanning calorimetry analysis.....	67
3.2.6	X-ray diffraction analysis.....	69
3.2.7	High performance liquid chromatography analysis .....	71
3.2.8	Experimental assessment of drug release from developed formulations .....	72
3.2.9	Rheological analysis of developed formulations .....	74
3.2.10	Texture analysis of developed formulations .....	79
3.2.10.1	Adhesiveness.....	80
3.2.10.2	Consistency .....	81
3.2.10.3	Gel strength .....	81
3.2.11	Data presentation and statistical treatment in figures and tables .....	82
<b>4</b>	<b>AQUEOUS SLN AND NLC DISPERSIONS.....</b>	<b>83</b>
<b>4.1</b>	<b>Development and characterization of clotrimazole-loaded SLN and NLC .....</b>	<b>85</b>
4.1.1	Assessment of the physical stability of the developed formulations .....	87
4.1.1.1	Immediately after production.....	87
4.1.1.2	At different temperatures of storage.....	88
4.1.1.3	During shelf life .....	89
4.1.2	Imaging analysis of Dynasan <sup>®</sup> 116-based lipid nanoparticles .....	91
4.1.3	Assessment of the physicochemical stability of clotrimazole.....	92
4.1.4	Assessment of the polymorphic behaviour of lipid and drug.....	95
4.1.4.1	Characterization of the bulk Dynasan <sup>®</sup> 116 .....	95
4.1.4.2	Characterization of the physical mixtures of bulk lipid and drug.....	99
4.1.4.2.1	DSC analysis.....	99
4.1.4.2.2	X-ray diffraction analysis .....	102
4.1.4.3	Characterization of the Dynasan <sup>®</sup> 116-based SLN and NLC .....	105
4.1.4.3.1	DSC analysis.....	106
4.1.4.3.2	X-ray diffraction analysis .....	110
4.1.5	Assessment of the chemical stability of clotrimazole in SLN and NLC.....	116
4.1.6	Rheological analysis of Dynasan <sup>®</sup> 116-based lipid nanoparticles .....	118
4.1.6.1	Immediately after production.....	118
4.1.6.2	At different temperatures of storage.....	121
4.1.6.3	During shelf life .....	123
<b>4.2</b>	<b>Development and characterization of ketoconazole-loaded SLN and NLC .....</b>	<b>125</b>

4.2.1	Assessment of the physical stability of the developed formulations .....	127
4.2.1.1	Immediately after production .....	128
4.2.1.2	At different temperatures of storage.....	129
4.2.1.3	During shelf life .....	131
4.2.2	Imaging analysis of Compritol <sup>®</sup> 888-based lipid nanoparticles.....	133
4.2.3	Assessment of the physicochemical stability of ketoconazole.....	133
4.2.4	Assessment of the polymorphic behaviour of lipid and drug.....	137
4.2.4.1	Characterization of the bulk Compritol <sup>®</sup> 888 ATO .....	137
4.2.4.2	Characterization of the physical mixtures of bulk lipid and drug.....	141
4.2.4.2.1	DSC analysis.....	141
4.2.4.2.2	X-ray diffraction analysis .....	144
4.2.4.3	Characterization of the Compritol <sup>®</sup> 888-based SLN and NLC.....	147
4.2.4.3.1	DSC analysis.....	147
4.2.4.3.2	X-ray diffraction analysis .....	149
4.2.5	Assessment of the chemical stability of ketoconazole in SLN and NLC.....	152
4.2.6	Rheological analysis of Compritol <sup>®</sup> 888-based lipid nanoparticles.....	154
4.2.6.1	Immediately after production .....	154
4.2.6.2	At different temperatures of storage.....	157
4.2.6.3	During shelf life .....	158
<b>5</b>	<b>SLN AND NLC BASED SEMI-SOLID FORMULATIONS.....</b>	<b>161</b>
<b>5.1</b>	<b>Incorporation of SLN and NLC into carbomer hydrogels.....</b>	<b>163</b>
5.1.1	Zeta potential and particle size parameters .....	164
5.1.2	Polymorphic behaviour of SLN and NLC entrapped into hydrogels.....	166
5.1.3	Mechanical characterization of semi-solid formulations .....	170
5.1.3.1	Rheological analysis.....	170
5.1.3.2	Texture analysis.....	177
5.1.3.2.1	Adhesiveness .....	177
5.1.3.2.2	Consistency.....	180
5.1.3.2.3	Gel strength.....	181
5.1.3.3	Correlation between rheological and texture properties .....	183
<b>5.2</b>	<b>Comparison of developed semi-solid formulations with commercial creams ....</b>	<b>186</b>
5.2.1	Particle size analysis.....	186

5.2.2	Clotrimazole release profile from semi-solid formulations .....	187
5.2.3	Mechanical characterization of semi-solid formulations .....	193
<b>6</b>	<b>CONCLUSIONS.....</b>	<b>197</b>
<b>7</b>	<b>REFERENCE LIST .....</b>	<b>204</b>
<b>8</b>	<b>ABBREVIATIONS .....</b>	<b>246</b>
<b>9</b>	<b>PUBLICATION LIST.....</b>	<b>248</b>
<b>10</b>	<b>ACKNOWLEDGEMENTS.....</b>	<b>255</b>
<b>11</b>	<b>CURRICULUM VITAE .....</b>	<b>257</b>